Document Type
Article
Publication Date
7-15-2024
Abstract
Sodium-glucose cotransporter type 2 inhibitors (SGLT2i) were initially recommended as oral anti-diabetic drugs to treat type 2 diabetes (T2D), by inhibiting SGLT2 in proximal tubule and reduce renal reabsorption of sodium and glucose. While many clinical trials demonstrated the tremendous potential of SGLT2i for cardiovascular diseases. 2022 AHA/ACC/HFSA guideline first emphasized that SGLT2i were the only drug class that can cover the entire management of heart failure (HF) from prevention to treatment. Subsequently, the antiarrhythmic properties of SGLT2i have also attracted attention. Although there are currently no prospective studies specifically on the anti-arrhythmic effects of SGLT2i. We provide clues from clinical and fundamental researches to identify its antiarrhythmic effects, reviewing the evidences and mechanism for the SGLT2i antiarrhythmic effects and establishing a novel paradigm involving intracellular sodium, metabolism and autophagy to investigate the potential mechanisms of SGLT2i in mitigating arrhythmias.
Recommended Citation
Duan, Hong-Yi; Barajas-Martinez, Hector; Antzelevitch, Charles; and Hu, Dan, "The Potential Anti-Arrhythmic Effect of SGLT2 Inhibitors" (2024). Department of Medicine Faculty Papers. Paper 458.
https://jdc.jefferson.edu/medfp/458
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.
PubMed ID
39010053
Language
English
Comments
This article is the author's final published version in Cardiovascular Diabetology, Volume 23, Issue 1, 2024, Article number 252.
The published version is available at https://doi.org/10.1186/s12933-024-02312-0.
Copyright © The Author(s) 2024